Literature DB >> 23560841

Treatment of hepatocellular carcinoma: present and future.

Chiara Genco1, Giuseppe Cabibbo, Marcello Maida, Giuseppe Brancatelli, Massimo Galia, Nicola Alessi, Giuseppe Butera, Claudio Genova, Piero Romano, Maurizio Raineri, Antonello Giarratano, Massimo Midiri, Calogero Cammà.   

Abstract

Hepatocellular carcinoma is a major health problem. It is the sixth most common cancer worldwide and the third most common cause of cancer-related death. Despite the availability of several treatment opportunities, diagnosis is still made in an advanced phase, limiting application of most therapeutic choices that currently are based on the Barcelona Clinic Cancer Liver Classification and include surgical resection, orthotopic liver transplantation and ablative methods for very early and early disease, arterial chemoembolization for intermediate stages and systemic therapy with sorafenib for advanced hepatocellular carcinoma. Thanks to novel advancements in knowledge of molecular pathogenesis of this tumor, many new systemic agents and locoregional treatments are in different stages of clinical development and they represent an important promise of further improvements in patients' survival.

Entities:  

Mesh:

Year:  2013        PMID: 23560841     DOI: 10.1586/era.13.21

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  12 in total

Review 1.  Imaging appearance of treated hepatocellular carcinoma.

Authors:  Francesco Agnello; Giuseppe Salvaggio; Giuseppe Cabibbo; Marcello Maida; Roberto Lagalla; Massimo Midiri; Giuseppe Brancatelli
Journal:  World J Hepatol       Date:  2013-08-27

Review 2.  Diagnosis and treatment of hepatocellular carcinoma: An update.

Authors:  Javier Tejeda-Maldonado; Ignacio García-Juárez; Jonathan Aguirre-Valadez; Adrián González-Aguirre; Mario Vilatobá-Chapa; Alejandra Armengol-Alonso; Francisco Escobar-Penagos; Aldo Torre; Juan Francisco Sánchez-Ávila; Diego Luis Carrillo-Pérez
Journal:  World J Hepatol       Date:  2015-03-27

3.  Heterogeneity of The CD90+ Population in Different Stages of Hepatocarcinogenesis.

Authors:  Smathorn Thakolwiboon; Jianhui Zhu; Qixing Liang; Theodore H Welling; Min Zhang; David M Lubman
Journal:  J Proteomics Bioinform       Date:  2014-09-12

Review 4.  Alcohol and hepatocellular carcinoma: a review and a point of view.

Authors:  Gianni Testino; Silvia Leone; Paolo Borro
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

5.  Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.

Authors:  Jia-Yan Ni; Hong-Liang Sun; Yao-Ting Chen; Jiang-Hong Luo; Dong Chen; Xiong-Ying Jiang; Lin-Feng Xu
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

6.  Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure.

Authors:  Marcello Maida; Massimo Iavarone; Maurizio Raineri; Calogero Cammà; Giuseppe Cabibbo
Journal:  World J Hepatol       Date:  2015-08-18

7.  DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro.

Authors:  Yao Huang; Jianxing Zeng; Teng Liu; Qingyi Xu; Xianglin Song; Jinhua Zeng
Journal:  Cancer Manag Res       Date:  2020-05-08       Impact factor: 3.989

8.  Identification of genes predicting unfavorable prognosis in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Meng Sha; Jie Cao; Zhi-Peng Zong; Ning Xu; Jian-Jun Zhang; Ying Tong; Qiang Xia
Journal:  Ann Transl Med       Date:  2021-06

9.  Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response.

Authors:  Giuseppe Cabibbo; Marcello Maida; Chiara Genco; Nicola Alessi; Marco Peralta; Giuseppe Butera; Massimo Galia; Giuseppe Brancatelli; Claudio Genova; Maurizio Raineri; Emanuele Orlando; Simona Attardo; Antonino Giarratano; Massimo Midiri; Vito Di Marco; Antonio Craxì; Calogero Cammà
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

10.  Plasmid transfer of plasminogen K1-5 reduces subcutaneous hepatoma growth by affecting inflammatory factors.

Authors:  Lea A Koch; Volker Schmitz; Christian P Strassburg; Esther Raskopf
Journal:  Biomed Res Int       Date:  2014-05-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.